Relmada Therapeutics Inc (RLMD) — Cash Flow-to-Debt Ratio
Relmada Therapeutics Inc (RLMD) has a Cash Flow-to-Debt Ratio of -0.91x as of March 2026, meaning its operating cash flow of $-15.07 Million could theoretically repay -1% of its total liabilities ($16.63 Million) in one year. See financial flexibility index of Relmada Therapeutics Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Relmada Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Relmada Therapeutics Inc across 15 annual periods. For the full cash flow conversion analysis, see how efficiently does Relmada Therapeutics Inc generate cash.
Annual Cash Flow-to-Debt Ratio for Relmada Therapeutics Inc (2012–2025)
Year-by-year debt coverage analysis for Relmada Therapeutics Inc. Check earnings quality score of Relmada Therapeutics Inc to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -6.11x | $-45.79 Million | $7.49 Million | ▼ -21.6% |
| 2024 | -5.03x | $-51.76 Million | $10.30 Million | ▼ -18.7% |
| 2023 | -4.24x | $-51.66 Million | $12.19 Million | ▲ +49.1% |
| 2022 | -8.32x | $-103.80 Million | $12.47 Million | ▼ -36.5% |
| 2021 | -6.10x | $-91.87 Million | $15.06 Million | ▼ -176.5% |
| 2020 | -2.21x | $-27.81 Million | $12.60 Million | ▼ -26501.5% |
| 2019 | -0.01x | $-12.09K | $1.46 Million | ▲ +98.8% |
| 2018 | -0.70x | $-6.00 Million | $8.56 Million | ▲ +85.1% |
| 2017 | -4.70x | $-6.47 Million | $1.38 Million | ▼ -14.4% |
| 2016 | -4.11x | $-13.14 Million | $3.20 Million | ▼ -294.2% |
| 2015 | -1.04x | $-16.23 Million | $15.58 Million | ▲ +0.0% |
| 2014 | -1.04x | $-16.23 Million | $15.58 Million | ▼ -1149.3% |
| 2014 | -0.08x | $-2.24 Million | $26.87 Million | ▼ -18788.6% |
| 2013 | 0.00x | $-11.86K | $26.87 Million | ▲ +100.0% |
| 2012 | -1.08x | $-7.57K | $7.00K | — |